Page 4 - Trappsol Cyclo News Today

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) COO Jeffrey Tate bought 29,941 shares of the stock in a transaction on Thursday, April 20th. The stock was purchased at an average cost of $0.71 per share, for a total transaction of $21,258.11. Following the acquisition, the chief operating officer now directly owns 62,101 shares of the […]

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) Director Markus Sieger acquired 59,881 shares of Cyclo Therapeutics stock in a transaction dated Thursday, April 20th. The stock was purchased at an average cost of $0.71 per share, with a total value of $42,515.51. Following the completion of the purchase, the director now owns 161,051 shares of […]

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) COO Jeffrey Tate acquired 29,941 shares of the business’s stock in a transaction on Thursday, April 20th. The stock was acquired at an average price of $0.71 per share, with a total value of $21,258.11. Following the transaction, the chief operating officer now directly owns 62,101 shares of […]

21.04.2023 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ...

Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) and Verde Clean Fuels (NASDAQ:VGAS – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability. Earnings & Valuation This table compares Cyclo Therapeutics […]

Maxim Group cut shares of Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) from a buy rating to a hold rating in a research report sent to investors on Monday, The Fly reports. Cyclo Therapeutics Price Performance Shares of CYTH stock opened at $0.92 on Monday. The stock has a market cap of $9.71 million, a P/E […]

09.01.2023 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ... Seite 1

18.10.2022 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ... Seite 1

16.08.2022 - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, ...

The Niemann-Pick Type C disease market is expected to grow from $128.35m last year to $188.35m in 2031 across the 3MM.